Form 8-K - Current report:
SEC Accession No. 0001193125-25-092435
Filing Date
2025-04-24
Accepted
2025-04-24 09:05:50
Documents
15
Period of Report
2025-04-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d787196d8k.htm   iXBRL 8-K 28006
2 EX-99.1 d787196dex991.htm EX-99.1 9673
6 GRAPHIC g787196g47k99.jpg GRAPHIC 4300
  Complete submission text file 0001193125-25-092435.txt   171088

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eq-20250424.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eq-20250424_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eq-20250424_pre.xml EX-101.PRE 11262
18 EXTRACTED XBRL INSTANCE DOCUMENT d787196d8k_htm.xml XML 3668
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38692 | Film No.: 25863879
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)